TuHURA Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HURA and other ETFs, options, and stocks.

About HURA

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. 

CEO
James A. Bianco
CEOJames A. Bianco
Employees
19
Employees19
Headquarters
Tampa, Florida
HeadquartersTampa, Florida
Founded
2023
Founded2023
Employees
19
Employees19

HURA Key Statistics

Market cap
46.05M
Market cap46.05M
Price-Earnings ratio
-1.12
Price-Earnings ratio-1.12
Dividend yield
Dividend yield
Average volume
280.47K
Average volume280.47K
High today
$0.7602
High today$0.7602
Low today
$0.7073
Low today$0.7073
Open price
$0.72
Open price$0.72
Volume
339.33K
Volume339.33K
52 Week high
$5.27
52 Week high$5.27
52 Week low
$0.70
52 Week low$0.70

Stock Snapshot

With a market cap of 46.05M, TuHURA Biosciences(HURA) trades at $0.76. The stock has a price-to-earnings ratio of -1.12.

As of 2026-01-14, TuHURA Biosciences(HURA) stock has fluctuated between $0.71 and $0.76. The current price stands at $0.76, placing the stock +7.4% above today's low and -0.0% off the high.

The TuHURA Biosciences(HURA)'s current trading volume is 339.33K, compared to an average daily volume of 280.47K.

During the past year, TuHURA Biosciences(HURA) stock moved between $0.70 at its lowest and $5.27 at its peak.

During the past year, TuHURA Biosciences(HURA) stock moved between $0.70 at its lowest and $5.27 at its peak.

People also own

Based on the portfolios of people who own HURA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .